

Duchenne Muscular Dystrophy Drugs Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/DC692CC7A857EN.html>

Date: February 2022

Pages: 63

Price: US\$ 3,250.00 (Single User License)

ID: DC692CC7A857EN

Abstracts

This report contains market size and forecasts of Duchenne Muscular Dystrophy Drugs in Global, including the following market information:

Global Duchenne Muscular Dystrophy Drugs Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Duchenne Muscular Dystrophy Drugs market was valued at 1041.1 million in 2021 and is projected to reach US\$ 7464.7 million by 2028, at a CAGR of 32.5% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Molecular-based Therapies Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Duchenne Muscular Dystrophy Drugs include Biogen, Roche, Daiichi Sankyo, Pfizer, Cumberland Pharmaceuticals, Santhera Pharmaceuticals, Taiho Pharmaceutical, Teijin Pharma and Akashi Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Duchenne Muscular Dystrophy Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends,

drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Duchenne Muscular Dystrophy Drugs Market, by Type, 2017-2022, 2023-2028
(\$ millions)

Global Duchenne Muscular Dystrophy Drugs Market Segment Percentages, by Type,
2021 (%)

Molecular-based Therapies

Steroid Therapy

Other

Global Duchenne Muscular Dystrophy Drugs Market, by Application, 2017-2022,
2023-2028 (\$ millions)

Global Duchenne Muscular Dystrophy Drugs Market Segment Percentages, by
Application, 2021 (%)

Hospitals

Clinics

Others

Global Duchenne Muscular Dystrophy Drugs Market, By Region and Country,
2017-2022, 2023-2028 (\$ Millions)

Global Duchenne Muscular Dystrophy Drugs Market Segment Percentages, By Region
and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Duchenne Muscular Dystrophy Drugs revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Duchenne Muscular Dystrophy Drugs revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Biogen

Roche

Daiichi Sankyo

Pfizer

Cumberland Pharmaceuticals

Santhera Pharmaceuticals

Taiho Pharmaceutical

Teijin Pharma

Akashi Therapeutics

Sarepta Therapeutics

BioMarin

Fibrogen Inc

Nobelpharma Co. Ltd

Eloxx Pharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Duchenne Muscular Dystrophy Drugs Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Duchenne Muscular Dystrophy Drugs Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS OVERALL MARKET SIZE

- 2.1 Global Duchenne Muscular Dystrophy Drugs Market Size: 2021 VS 2028
- 2.2 Global Duchenne Muscular Dystrophy Drugs Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Duchenne Muscular Dystrophy Drugs Players in Global Market
- 3.2 Top Global Duchenne Muscular Dystrophy Drugs Companies Ranked by Revenue
- 3.3 Global Duchenne Muscular Dystrophy Drugs Revenue by Companies
- 3.4 Top 3 and Top 5 Duchenne Muscular Dystrophy Drugs Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Duchenne Muscular Dystrophy Drugs Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Duchenne Muscular Dystrophy Drugs Players in Global Market
 - 3.6.1 List of Global Tier 1 Duchenne Muscular Dystrophy Drugs Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Duchenne Muscular Dystrophy Drugs Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Duchenne Muscular Dystrophy Drugs Market Size Markets, 2021 & 2028

4.1.2 Molecular-based Therapies

4.1.3 Steroid Therapy

4.1.4 Other

4.2 By Type - Global Duchenne Muscular Dystrophy Drugs Revenue & Forecasts

4.2.1 By Type - Global Duchenne Muscular Dystrophy Drugs Revenue, 2017-2022

4.2.2 By Type - Global Duchenne Muscular Dystrophy Drugs Revenue, 2023-2028

4.2.3 By Type - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Duchenne Muscular Dystrophy Drugs Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinics

5.1.4 Others

5.2 By Application - Global Duchenne Muscular Dystrophy Drugs Revenue & Forecasts

5.2.1 By Application - Global Duchenne Muscular Dystrophy Drugs Revenue, 2017-2022

5.2.2 By Application - Global Duchenne Muscular Dystrophy Drugs Revenue, 2023-2028

5.2.3 By Application - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Duchenne Muscular Dystrophy Drugs Market Size, 2021 & 2028

6.2 By Region - Global Duchenne Muscular Dystrophy Drugs Revenue & Forecasts

6.2.1 By Region - Global Duchenne Muscular Dystrophy Drugs Revenue, 2017-2022

6.2.2 By Region - Global Duchenne Muscular Dystrophy Drugs Revenue, 2023-2028

6.2.3 By Region - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Duchenne Muscular Dystrophy Drugs Revenue, 2017-2028

6.3.2 US Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.3.3 Canada Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.3.4 Mexico Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Duchenne Muscular Dystrophy Drugs Revenue, 2017-2028

6.4.2 Germany Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.4.3 France Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.4.4 U.K. Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.4.5 Italy Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.4.6 Russia Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.4.7 Nordic Countries Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.4.8 Benelux Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Duchenne Muscular Dystrophy Drugs Revenue, 2017-2028

6.5.2 China Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.5.3 Japan Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.5.4 South Korea Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.5.5 Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.5.6 India Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Duchenne Muscular Dystrophy Drugs Revenue, 2017-2028

6.6.2 Brazil Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.6.3 Argentina Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Duchenne Muscular Dystrophy Drugs Revenue, 2017-2028

6.7.2 Turkey Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.7.3 Israel Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.7.4 Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

6.7.5 UAE Duchenne Muscular Dystrophy Drugs Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Biogen

7.1.1 Biogen Corporate Summary

- 7.1.2 Biogen Business Overview
- 7.1.3 Biogen Duchenne Muscular Dystrophy Drugs Major Product Offerings
- 7.1.4 Biogen Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2017-2022)
- 7.1.5 Biogen Key News
- 7.2 Roche
 - 7.2.1 Roche Corporate Summary
 - 7.2.2 Roche Business Overview
 - 7.2.3 Roche Duchenne Muscular Dystrophy Drugs Major Product Offerings
 - 7.2.4 Roche Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2017-2022)
 - 7.2.5 Roche Key News
- 7.3 Daiichi Sankyo
 - 7.3.1 Daiichi Sankyo Corporate Summary
 - 7.3.2 Daiichi Sankyo Business Overview
 - 7.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Major Product Offerings
 - 7.3.4 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2017-2022)
 - 7.3.5 Daiichi Sankyo Key News
- 7.4 Pfizer
 - 7.4.1 Pfizer Corporate Summary
 - 7.4.2 Pfizer Business Overview
 - 7.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Major Product Offerings
 - 7.4.4 Pfizer Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2017-2022)
 - 7.4.5 Pfizer Key News
- 7.5 Cumberland Pharmaceuticals
 - 7.5.1 Cumberland Pharmaceuticals Corporate Summary
 - 7.5.2 Cumberland Pharmaceuticals Business Overview
 - 7.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Major Product Offerings
 - 7.5.4 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2017-2022)
 - 7.5.5 Cumberland Pharmaceuticals Key News
- 7.6 Santhera Pharmaceuticals
 - 7.6.1 Santhera Pharmaceuticals Corporate Summary
 - 7.6.2 Santhera Pharmaceuticals Business Overview
 - 7.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Major Product Offerings

7.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2017-2022)

7.6.5 Santhera Pharmaceuticals Key News

7.7 Taiho Pharmaceutical

7.7.1 Taiho Pharmaceutical Corporate Summary

7.7.2 Taiho Pharmaceutical Business Overview

7.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Major Product Offerings

7.7.4 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2017-2022)

7.7.5 Taiho Pharmaceutical Key News

7.8 Teijin Pharma

7.8.1 Teijin Pharma Corporate Summary

7.8.2 Teijin Pharma Business Overview

7.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Major Product Offerings

7.8.4 Teijin Pharma Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2017-2022)

7.8.5 Teijin Pharma Key News

7.9 Akashi Therapeutics

7.9.1 Akashi Therapeutics Corporate Summary

7.9.2 Akashi Therapeutics Business Overview

7.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Major Product Offerings

7.9.4 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2017-2022)

7.9.5 Akashi Therapeutics Key News

7.10 Sarepta Therapeutics

7.10.1 Sarepta Therapeutics Corporate Summary

7.10.2 Sarepta Therapeutics Business Overview

7.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Major Product Offerings

7.10.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2017-2022)

7.10.5 Sarepta Therapeutics Key News

7.11 BioMarin

7.11.1 BioMarin Corporate Summary

7.11.2 BioMarin Business Overview

7.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Major Product Offerings

7.11.4 BioMarin Duchenne Muscular Dystrophy Drugs Revenue in Global Market

(2017-2022)

7.11.5 BioMarin Key News

7.12 Fibrogen Inc

7.12.1 Fibrogen Inc Corporate Summary

7.12.2 Fibrogen Inc Business Overview

7.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Major Product Offerings

7.12.4 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Revenue in Global Market

(2017-2022)

7.12.5 Fibrogen Inc Key News

7.13 Nobelpharma Co. Ltd

7.13.1 Nobelpharma Co. Ltd Corporate Summary

7.13.2 Nobelpharma Co. Ltd Business Overview

7.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Major Product Offerings

7.13.4 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2017-2022)

7.13.5 Nobelpharma Co. Ltd Key News

7.14 Eloxx Pharmaceuticals

7.14.1 Eloxx Pharmaceuticals Corporate Summary

7.14.2 Eloxx Pharmaceuticals Business Overview

7.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Major Product Offerings

7.14.4 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue in Global Market (2017-2022)

7.14.5 Eloxx Pharmaceuticals Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Duchenne Muscular Dystrophy Drugs Market Opportunities & Trends in Global Market

Table 2. Duchenne Muscular Dystrophy Drugs Market Drivers in Global Market

Table 3. Duchenne Muscular Dystrophy Drugs Market Restraints in Global Market

Table 4. Key Players of Duchenne Muscular Dystrophy Drugs in Global Market

Table 5. Top Duchenne Muscular Dystrophy Drugs Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Duchenne Muscular Dystrophy Drugs Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Companies, 2017-2022

Table 8. Global Companies Duchenne Muscular Dystrophy Drugs Product Type

Table 9. List of Global Tier 1 Duchenne Muscular Dystrophy Drugs Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Duchenne Muscular Dystrophy Drugs Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Duchenne Muscular Dystrophy Drugs Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Duchenne Muscular Dystrophy Drugs Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Duchenne Muscular Dystrophy Drugs Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Duchenne Muscular Dystrophy Drugs Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Duchenne Muscular Dystrophy Drugs Revenue,

(US\$, Mn), 2017-2022

Table 21. By Country - North America Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2023-2028

Table 30. Biogen Corporate Summary

Table 31. Biogen Duchenne Muscular Dystrophy Drugs Product Offerings

Table 32. Biogen Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), (2017-2022)

Table 33. Roche Corporate Summary

Table 34. Roche Duchenne Muscular Dystrophy Drugs Product Offerings

Table 35. Roche Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), (2017-2022)

Table 36. Daiichi Sankyo Corporate Summary

Table 37. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product Offerings

Table 38. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), (2017-2022)

Table 39. Pfizer Corporate Summary

Table 40. Pfizer Duchenne Muscular Dystrophy Drugs Product Offerings

Table 41. Pfizer Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), (2017-2022)

Table 42. Cumberland Pharmaceuticals Corporate Summary

Table 43. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offerings

Table 44. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue

(US\$, Mn), (2017-2022)

Table 45. Santhera Pharmaceuticals Corporate Summary

Table 46. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offerings

Table 47. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), (2017-2022)

Table 48. Taiho Pharmaceutical Corporate Summary

Table 49. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product Offerings

Table 50. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), (2017-2022)

Table 51. Teijin Pharma Corporate Summary

Table 52. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product Offerings

Table 53. Teijin Pharma Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), (2017-2022)

Table 54. Akashi Therapeutics Corporate Summary

Table 55. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product Offerings

Table 56. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), (2017-2022)

Table 57. Sarepta Therapeutics Corporate Summary

Table 58. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product Offerings

Table 59. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), (2017-2022)

Table 60. BioMarin Corporate Summary

Table 61. BioMarin Duchenne Muscular Dystrophy Drugs Product Offerings

Table 62. BioMarin Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), (2017-2022)

Table 63. Fibrogen Inc Corporate Summary

Table 64. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product Offerings

Table 65. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), (2017-2022)

Table 66. Nobelpharma Co. Ltd Corporate Summary

Table 67. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product Offerings

Table 68. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Revenue (US\$, Mn), (2017-2022)

Table 69. Eloxx Pharmaceuticals Corporate Summary

Table 70. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offerings

Table 71. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue (US\$,

Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Duchenne Muscular Dystrophy Drugs Segment by Type in 2021
- Figure 2. Duchenne Muscular Dystrophy Drugs Segment by Application in 2021
- Figure 3. Global Duchenne Muscular Dystrophy Drugs Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Duchenne Muscular Dystrophy Drugs Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Duchenne Muscular Dystrophy Drugs Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2021
- Figure 8. By Type - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2017-2028
- Figure 12. US Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2017-2028
- Figure 16. Germany Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn),

2017-2028

Figure 23. By Region - Asia Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2017-2028

Figure 24. China Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028

Figure 28. India Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2017-2028

Figure 30. Brazil Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Duchenne Muscular Dystrophy Drugs Revenue Market Share, 2017-2028

Figure 33. Turkey Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Duchenne Muscular Dystrophy Drugs Revenue, (US\$, Mn), 2017-2028

Figure 37. Biogen Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Roche Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Pfizer Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Teijin Pharma Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. BioMarin Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Duchenne Muscular Dystrophy Drugs Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/DC692CC7A857EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DC692CC7A857EN.html>